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A MURINE MODEL OF POLYMYOSITIS INDUCED BY 
COXSACKIEVIRUS B1 (TUCSON STRAIN) 
STEVEN L. STRONGWATER, KATERINA DOROVINI-ZIS, RICHARD D. BALL, 
and THOMAS J. SCHNITZER 
A murine model of polymyositis induced by 
coxsackievirus B1, Tucson strain (CVBT) is described. 
Intraperitoneal CVBT inoculation of CD 1 Swiss mice 
less than 48 hours old resulted in proximal hindquarter 
weakness that was first apparent 7 days after viral 
challenge and persisted for more than 10 weeks. Electro- 
myographic and histologic evidence of a continuing 
myositis was present during this entire period of time. 
However, virus was not detectable later than 2 weeks 
post infection, despite clinical progression of disease. 
The finding of electromyographir and histologic abnor- 
malities in CVBT-infected mice, long after virus had 
cleared and neutralizing antibody production evoked, 
suggests that persistent myositis may be immunological- 
ly mediated, triggered by the initial acute viral infection. 
Polymyositis (PM) is a treatable myopathic 
disease whose etiology is unknown. Prcvious investi- 
gations of this disorder have centered on examining 
the role of viral infection and autoimmune dysfunction 
in the pathogenesis of PM, but to date these studies 
have failed to provide an understanding of the patho- 
genetic mechanisms involved (1). Further progress in 
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unraveling the etiology of this disorder has been 
hampered by lack of a good experimental model. 
Investigation of the role of virus in the patho- 
genesis of PM dates back to 1959 when Sussman et al 
isolated coxsackievirus B (CVB) from the muscle of a 
1-year-old child who died of a diffuse myositis (2). 
Numerous subsequent investigators have identified 
picornavirus-like particles by electron microscopic 
(EM) examination of clinically involved muscle from 
patients with PM (3-5). The importance of these 
reports is further supported by the demonstration of a 
serial rise in serum neutralizing antibody titers to CVB 
in several patients who developed PM (6) and isolation 
of CVB from the stool and muscle of a patient with 
fatal PM (5). As well, CVB has been implicated in 
other human muscle disorders (i.e., Bornholm disease 
or epidemic myalgia) in which viral rcplication in 
skeletal muscle is thought to be responsible for clinical 
manifestations (7). 
Recently, a number of disorders in mice have 
been shown to arise as a consequence of CVB infec- 
tion (8,9). Studying the pathogenesis of diabetes melli- 
tus (DM), Yoon et a1 were able to develop strains of 
CVB that, upon infection, rcsulted in the selective 
destruction of pancreatic beta cells and the subsequent 
development of clinical DM (8). Virologic studies and 
serial determination of anti-CVB titers in the mice as 
well as in humans with juvenile onset DM have 
confirmed the importance of these findings (10). The 
etiologic role of CVB in chronic myocarditis has 
similarly been examined in a murine system. Data 
from the latter studies suggest that CVB infection may 
stimulate autoimmune destruction of myocardial tis- 
sue. Thcse observations have recently been extended 
to primates (11,12). 
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Such investigations thus underscore the poten- 
tial role of CVB in triggering autoimmune disorders as 
well as the  importance of murine models in elucidating 
the pathophysiology of human disease. Therefore, 
based on reports confirming the  myotropism of CVB,  
the documented role of C V B  in stimulating the  devcl- 
opment of other postulated autoimmune disorders, 
and strong support in the  literature implicating C V B  
pathogenetically in the  development of PM, w e  under- 
took to develop the  murine CVB-induced model of PM 
described below. 
MATERIALS AND METHODS 
Virus and cells. CVB isolates with known myotro- 
pism were obtained from Dr. L. Minnich, University of 
Arizona (CVB 1, Tucson, CVBT) and Dr. C. Gauntt, Univer- 
sity of Texas (CVB 3, Woodruff strain, myocarditic). CVB 
with undefined myotropisms were also examined; these 
included clinical isolates of CVB 1, 4, 5, and 6 (Clin 1 ,  4, 5, 
and 6, respectively) obtained from the virology laboratory of 
The University of Michigan Medical Center, and an amyo- 
carditic strain of CVB 3, supplied by Dr. C. Gauntt. All 
viruses were maintained and plaque-purified 3 times in either 
Vero or Buffalo green monkey kidney (BMK) cells. Virus 
was stored at -70°C. All dilutions of virus used in vivo were 
made in phosphate buffered saline (PBS). The working 
inoculum of virus selected for all studies was that dose which 
resulted in the greatest morbidity (proximal limb girdle 
weakness) and overall lowest mortality. 
Tissue culture. Virus was propagated in BMK cell 
monolayers by standard techniques (7). Muscle tissues ex- 
amined for the presence of infectious virus were obtained 
from the proximal extensor muscles of the right hindlimb, 
diaphragm, and heart by blunt dissection and ground using a 
mortar and pestle in 2 ml Dulbecco’s modified essential 
medium (DMEM) and sand. The slurry was then spun at 
2,000 revolutions per minute for 10 minutes and the superna- 
tant used to infect BMK cell monolayers (7). Plaques were 
counted after 48 hours of incubation at 37°C in a 5% COz 
atmosphere, 12 hours following neutral red overlay. Results 
are expressed as the log,, of the number of plaque-forming 
units (PFU) per ml. 
Animals used and experimental design. CD 1 Swiss 
mice, a murine line previously reported to develop focal 
myositis, wcre used in all experiments. Pregnant breeder 
females were obtained from the Charles River Breeding 
Laboratories (Portage, MI) and allowed to deliver. Offspring 
were then randomly selected, inoculated, and caged sepa- 
rately in groups of 7-10 animals with surrogate mothers. 
Mice were challenged intraperitoneally (IP) at less than 48 
hours of age with serial tenfold dilutions of 0.1 cc virus or 
PBS (control), using a Hamilton syringc to ensure accurate 
delivery of the inoculum. Animals were observed daily for 
clinical evidence of muscle weakness. Groups of 5-10 were 
killed every other day during the first 7 days of the study and 
thereafter weekly by cervical dislocation for histologic and 
serologic examinations. Serum samples were obtained by 
subclavian cutdown and processed individually or pooled 
when only small quantities were obtained. All serum sam- 
ples were stored at -20°C. 
Histopathologic studies. All tissue samples were ob- 
tained immediately after killing and fixed in either 10% 
paraformaldehyde or 2% glutaraldehyde or snap-frozen in 
isopentane cooled in liquid nitrogen for light microscopy, 
electron microscopy or frozen section studies, respectively 
(13). Several tissues were examined for evidence of viral 
infection; these included liver, hcart, peripheral nerves, and 
central nervous system tissue, as well as skeletal muscle and 
the diaphragm. 
Immunofluorescence studies. Transverse and longitu- 
dinal sections (8p) of right hindquarter muscle tissue, mount- 
ed on cover slips and fixed for 20 minutes in cold acetone 
(-2O”C), were examined by indirect immunofluorescence for 
CVB 1 antigens. A 1:32 dilution of monkey anti-CVB I 
serum (lop, NIH reference research sera, Bethesda, MD) 
was applied to fixed tissue which was incubated in a moist 
chamber at room temperature for 1 hour. The cover slips 
were then washed in PBS for 20 minutes, followed by 
application of FITC-conjugated goat anti-monkey gamma 
globulin (Antibodies Inc., La Jolla, CA) and incubated in a 
moist chamber for 1 hour at 37°C. Just prior to mounting of 
these tissues in Elvanol, the cover slips were again washed 
in PBS (10 minutes) then distilled water (30 seconds), and 
counterstained for 5 seconds in Eriochrome black. 
Antibody determinations. The functional ability of 
serum to neutralize CVBT was studied by a microneutraliza- 
tion assay. Briefly, serial fourfold dilutions of heat-inactivat- 
ed (30 minutes, 56°C) serum from CVBT-infected and control 
mice, diluted in 10% heat-inactivated newborn calf serum 
and DMEM, were incubated with lo6 PFU/ml CVBT at 37°C 
for 1 hour. Two hundred microliters of the incubated sample 
was then added to microtiter wells containing BMK mono- 
layers and allowed to incubate at 37°C in a 5% COz atmo- 
sphere overnight. The cells were then fixed with 20% 
formaldehyde and stained with Giemsa stain. Fifty percent 
neutralization of CVBT was recorded and the neutralization 
titer expressed as logz of the reciprocal. 
Electromyography (EMG). Serial EMGs were per- 
formed on both CVB-challenged and control mice. All 
animals wcre anesthetized with sodium pentothal, 5 mg/ml, 
0.3-0.8 muanimal. Dosages were titrated to keep the animals 
as lightly anesthetized as possible. Mice were restrained on 
their backs and the skin and superficial tissues of the 
abdomen and right limb incised and reflected to expose the 
musculature of the limbs. In mice less than 18 days old, both 
hindlimbs were examined. In older mice, only the right 
hindlimb was subjected to investigation. The muscles of the 
leg proper were considered “distal,” whereas those of the 
thigh were considered “proximal.” No attempts were made 
to evaluate individual muscles within these groups due to the 
relative size of the concentric needle as compared with the 
muscle fibers. Concentric needle electrodes (DISA 13130, 
30 mm long, 0.45 mm diameter) were used throughout the 
study. All examinations were performed using a TECA TD- 
20 EMG machine. Attempts to evaluate motor unit action 
potentials (MUAP) were not made since they were rarely 
seen and, when visualized, usually accompanied tremor or 
myoclonic jerking, thus making them unsuitable for analysis. 
Since it was impossible to produce voluntary movements, 
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electromyographic evaluation of interference patterns was 
also not performed. 
RESULTS 
Identification of myotropic virus. Of the 7 CVB 
strains initially screened in the mice (CVBT, CVB 3 
myocarditic [Woodrurn, CVB 3 amyocarditic, and 
Clin 1 ,  4, 5 ,  and 6), 3 produced clinical muscle 
weakness: in Clin 1- and Clin 6-infected animals these 
symptoms resulted from primary neurologic damage, 
while disease induced by CVBT was due to histologi- 
cally demonstrated myositis. Subsequent studies were 
hence performed using plaque-purified CVBT. An in- 
fectious IP dose of 3 x 10' PFU was used in all 
subsequent experiments after preliminary studies re- 
vealed that this inoculum was optimal, producing 
clinical limb girdle proximal muscle weakness in 70- 
80% of challenged animals with an accompanying 
mortality of less than 30%. Studies using large num- 
bers of mice have repeatedly substantiatcd thcse find- 
ings (Figure I ) .  
Clinical symptoms. Clinical evidence of muscle 
disease was occasionally observed as early as 4-5 days 
after infection, but more commonly was apparent 7-1 0 
days following viral challenge. Characteristically, 
muscle weakness was evident in the proximal extensor 
muscle groups of both hindquarters with one limb 
often being preferentially affected. This resulted in a 
waddling gait, thereby simplifying clinical recognition 
of disease. Weakness increased in severity throughout 
the first 3 weeks following inoculation, after which it 
stabilized but persisted for the length of the experi- 
ment. As many as 70-80% of surviving animals devel- 
oped clinical evidence of myositis. No weakness was 
ever observed in the control animals. There was, 
additionally, no significant difference in the growth 
and development of virus-infected mice as compared 
with controls (Figure 1). 
Histopathology. In the inoculated animals the 
pathologic changes varied in scverity among animals, 
and even in the same animal among different muscle 
groups. For each reported observation, 2-5 animals 
were examined. In all CVB-infected mice, the hip 
extensors showed the most extensive and severe 
changes. Furthermore, even within the same muscle 
the distribution, extent, and intensity of the lesions 
were different among various fascicles. The earliest 
changes were observed on day 4 and consisted of 
interstitial edema and acute necrosis of isolated mus- 
cle fibers which were surrounded by acute and chronic 
CVE challenged (n= 140) 0 
PBS controls (n= 701 C, 
0 1 2 3 4 6 
weeks post challenge 
Figure 1. Coxsackievirus B 1, Tucson strain (CVBT)-induced murine 
polymyositis. One hundred forty mice less than 48 hours old wcre 
challenged intrapcritoncally with CVBT; 70 animals treated with 
phosphate buffercd saline (PBS) were used a s  controls. Clinical 
symptoms were manifested within 7-10 days. 
inflammatory cells. On day 6 there was widespread 
necrosis of muscle cells, severe interstitial edema, and 
diffuse infiltration with polymorphonuclear leuko- 
cytes, lymphocytes, and plasma cells. Phagocytosis of 
necrotic fiber segments was evident. 
These changes were also prominent on day 8 
(Figure 2). By then, active regeneration of muscle cells 
was apparent, characterized by numerous slender, 
basophilic myotubes with central vesicular nuclei and 
prominent nucleoli. Occasional cells were undergoing 
mitosis (see insert Figure 2), but their definite identifi- 
cation as either myoblasts or other interstitial cells was 
not possible. 
Fairly extensive dystrophic myofiber calcifica- 
tions were also present from days 8-14 and to a lesser 
extent throughout the study. By day 14 marked varia- 
tion in fiber size, centralization of myocyte nuclei, 
rounding of cell contours, and focal round cell infil- 
trates with occasional eosinophils, commonly sur- 
rounding blood vessels or dystrophic calcifications, 
were prominent (Figure 3). On day 21 adipose tissue 
began to replace lost myofibers (Figure 4). Myocyte 
regeneration remained active and could be seen in 
some animals as late as 72 days. 
Overall there appeared to be an initial acute 
generalized inflammatory reaction which progressed 
to a stage of focal, chronic inflammation and then 
gradually began to resolve (Figure 5 ) .  At no stage were 
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Figure 2. Eight days after inoculation with coxsackievirus BI,  Tucson strain. Phagocytosis of necrotic muscle 
fibers, diffuse and perivascular acute and chronic inflammatory rcaction, regeneration (arrows), and 
occasional mitotic figures (insert) (hematoxylin and eosin, original magnification x 470). 
Figure 3. Fourteen days after inoculation with coxsackievirus BI ,  Tucson strain. Dystrophic calcification of 
muscle cells. Interstitial inflammation is less intense than in Figure 2. Many muscle fibers have central nuclei 
(hematoxylin and eosin, original magnification X 470). 
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Figure 4. Twenty-one days after inoculation with coxsackievirus B I ,  Tucson strain. Fat replacement, 
prominent in the involved fascicles. Inflammatory cclls mainly gathered about areas of calcification. 
Surviving muscle fibers have rounded contours and central nuclei (hematoxylin and eosin, original 
magnification x 296). 
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Figure 5. Fifty-four days after inoculation with coxsackievirus BI,  Tucson strain. Fat replacement. 
Occasional calcified muscle cells still present (hematoxylin and eosin, original magnification x 296). 
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Table 1. Electromyography findings after challenge with 




Experi- Days from Fibrilla- sharp dis- 
ment challenge tions waves charges 
~ ~ ~ 
1 11 -+  + Profuse 
2 18 + + Moderate 
3 24 + 0 Minimal 
4 32 0 0 Minimal 
5 39 0 0 Minimal 
6 46 0 0 0 
7 53 0 0 Minimal 
* Age-matched controls demonstrated no significant electromyo- 
graphic abnormalities. 
there was a decrease in the extent of these abnormali- 
ties with time. A neurogenic etiology for these abnor- 
malities could not be ruled out by EMG alone due to 
the inability to accurately evaluate MUAPs. However, 
histologic studies (above) suggested relative sparing of 
neurologic tissue by CVBT infection. Control animals 
did display a significant amount of “spontaneous 
activity” consisting of short-duration (1-2 ms) spike 
potentials with an initial negative deflection consistent 
with endplate phenomenon. These were, however, 
easily distinguishable from the pathologic abnormali- 
ties observed in the infected mice. 
Virus recovery. CVB has recognized myotro- 
pism and is thought to induce its pathology by direct 
tissue lysis. In self-limited viral illnesses, the normal 
host is usually capable of clearing virus within 2 weeks 
(7) .  The continued presence of infectious viral parti- 
cles in muscle tissue for longer periods would directly 
implicate CVBT in the myopathic process which, by 
clinical and electromyographic evidence, appeared to 
persist for at least 7 weeks. Attempts were therefore 
made to examine for persistence of infectious virus in 
3 separate organs: diaphragm, cardiac, and skeletal 
muscle (Table 2, Figure 8). 
Virus was first recovered 2 days following IP 
challenge, with peak titers of infectious virus cultured 
from both diaphragm and skeletal muscle on the fifth 
and sixth days after viral challenge. CVB titers were 
highest in skeletal muscle, followed by diaphragmatic 
tissues. Virus was entirely cleared first from cardiac 
tissue, followed by the diaphragm and skelctal muscle 
on days 8, 10, and 14, respectively. The short-lived 
presence and low concentration of virus (< lo2  
PFU/ml) in cardiac tissues probably reflect transient, 
early viremia: the histologic appearance of the heart 
did not reflect CVB-induced lytic injury, as opposed to 
Table 2. 
BI,  Tucson strain (CBVT) 
Persistence of virus after challenge with coxsackievirus 
Peak CVBT Culture negative 
titer (days from chal- 
Tissue (loglo)* lenge) 






* Plaque-forming unitshl.  
t Right hindquarter extensor muscle tissue. 
the generalized inflammation seen in skeletal muscle. 
The inability to recover virus from any muscle tissues 
after 2 weeks argues against a primary lytic process 
mediating the observed myopathy which persists for 
months. 
Examination for viral antigens. To examine the 
possibility that noninfectious forms of virus persisted 
in CVBT-challenged animals, indirect immunofluores- 
cence examination of hindquarter proximal muscle 
tissue for the presence of CVB or CVB-associated 
antigens was performed in control and infected ani- 
mals. CVB antigens were first detected 6 days post 
infection, and antigen expression was greatest on days 
9-12. Figures 9A and 9B illustrate the appearance of 
positively and negatively immunofluorescent muscle 
tissue from an uninfectcd and an infected animal, 
respectively. In pathologically involved muscle, im- 






M CVB TITER ofulml 
* .......... ......... ...._____ 
.... 
1 2 3 4 5 6  
TIME (WEEKS) 
Figure 8. Coxsackievirus BI , Tucson strain (CVBT) recovery from 
right hindquarter extensor muscle and antibody response to CVBT 
challenge, as assessed by microneutralization assay. Significant 
antibody titers began to rise after 7 days and reached peak concen- 
trations by 3 weeks. Virus was entirely cleared after 2 weeks. PFU 
= plaque-forming units. 
440 STRONGWATER ET AL 
A 
B 
Figure 9. Indirect immunofluorescence of control (A) and coxsackievirus B l ,  Tucson strain (CVB.r)- 
challenged (B) mice 9 days following treatment. Positive immunofluorescence is bright white (B) and reflects 
the presence of CVBT or the group B specific antigen (original magnification x 400). 
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individual myofibers, consistent with previously dem- 
onstrated intracytoplasmic picornavirus replication. 
By 2 weeks post infection, all tissues studied had no 
demonstrable evidence of CVB antigens. Parallel his- 
tologic studies on frozen section materials examined at 
14 days or later confirmed the presence of ongoing 
myositis despite the negative immunofluorescence 
findings. 
Antibody determinations. To assess the humoral 
immune response of mice to CVBT challenge, specific 
serum antibody titers directed against CVB were mea- 
sured by a microneutralization assay. A rise in anti- 
CVB immunoglobulin titer was first detected by day 6 
in infected animals. By day 12 there was an eightfold 
increase in serum neutralizing capacity. Neutralizing 
titers thereafter remained elevated throughout the 6- 
week experimental period (Figure 8). 
DISCUSSION 
Significant progress in understanding the patho- 
genesis of polymyositis has been hampered by the lack 
of an appropriate experimental model. Earlier at- 
tempts to develop an animal system in which to study 
this disease have been patterned after other successful 
models of autoimmune disorders, such as experimen- 
tal allergic encephalitis and autoimmune myasthenia 
gravis and have resulted in the description of a myo- 
pathic model, experimental allergic myositis (EAM), 
which develops as a consequence of repetitive chal- 
lenge with homologous or heterologous muscle tissue 
in complete Freund’s adjuvant (1,14). 
This model suffers from several major short- 
comings when compared with human PM: 1) Muscle 
weakness is often subclinical and thus difficult to 
detect; 2 )  An accompanying adjuvant-induced arthritis 
hampers clinical evaluation of muscle disease; 3 )  
There is frequently a 6-week delay until the myositis 
begins; 4) The disease is monophasic and short-lived; 
5) To foster continued myositis, “booster” injections 
are necessary; and finally 6) The nature of the antigen 
responsible for the muscle disease has not been clearly 
defined. Thus, there is a clear need for an experimen- 
tal model which more closely resembles the clinical 
and laboratory features of PM and which can be easily 
manipulated in subsequent laboratory investigations. 
The CVB-induced rnurine model of PM de- 
scribed in this paper differs significantly from others 
studicd and closely approximates the human disorder. 
The cardinal clinical feature of PM is proximal muscle 
weakness. In the model described herein, mice infect- 
ed as neonates with sublethal doses of CVB.r clearly 
developed weakness which preferentially affected the 
proximal muscle groups. The onset of these symptoms 
occurred shortly after viral challenge, often as soon as 
4 days following infection. Muscle weakness was 
progressive, much as in humans, ultimately affecting 
the ability of these animals to ambulate normally. 
Daily inspection confirmed the progressive nature of 
this syndrome. which persisted well beyond what 
would be expected from a self-limited viral illness. 
Muscle weakness increased in severity for 3 weeks 
and was easily recognizable for as long as 10 weeks. 
Despite the severity of the developing myositis, there 
was no significant difference in the growth pattern of 
infected animals as compared with controls, emphasiz- 
ing the selective nature of this disease (Figure 1). 
The pathologic features of murine CVBT-in- 
duced murine myositis paralleled those seen in human 
PM. There was evidence of selective muscle tissue 
involvement, characterized by mononuclear cell infil- 
trates accompanied by degenerating and regenerating 
myofibers. Histologic abnormalities, first evident on 
day 4, consisted of intense and generalized muscle 
tissue inflammation (Figures 1-5). By 2 weeks after 
infection, when muscle weakness was clinically pro- 
gressive, the myositis had become more focal and was 
almost indistinguishable from that seen in human PM. 
Ongoing muscle tissue inflammation persisted with 
easily recognizable pathologic abnormalities for at 
least 6 weeks, long after infectious virus had cleared 
(Figure 8). Transient myocyte calcifications were pre- 
sent for 3 weeks, and may be related to the calcinosis 
which accompanies childhood PM, but the explanation 
for this finding is not clear. 
Despite the fact that infectious virus could be 
recovered in tissue culture for at least 2 weeks post 
infection and viral antigen could be detected by immu- 
nofluorescence for an equivalent period of time, elec- 
tron microscopic examination of this tissue failed to 
reveal the icosahedral particles characteristic of picor- 
navirus known to be present by culture techniques. 
These findings emphasize that EM examination is not 
a sensitive means of screening for viral involvement in 
disease and may help explain why viral particles are 
not detected more frequently in cases of human PM. 
Although there is little question that CVBT 
infection played a primary role in the development of 
early myositis, the exact mechanisms responsible for 
prolonged muscle tissue injury are unclear. At least 
two hypotheses can be advanced to explain the CVB- 
induced disease: 1) Either primary CVB infection of 
skeletal muscle myofibers resulted in myolysis, atten- 
dant release of inflammatory mediators, and the ob- 
served pathology and clinical symptoms which only 
very gradually resolved, and/or 2 )  the virus stimulated 
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a host response capable of perpetuating a myositis. 
Three lines of experimental evidence presented above 
tend to support the latter hypothesis. First, virus could 
not be detected by either direct culture or EM studies 
beyond 2 weeks after infection, yet muscle weakness 
remained progressive and electromyographic and his- 
tologic evidence of ongoing myositis persisted for long 
periods of time thereafter. Second, indirect immuno- 
fluorescence failed to reveal the presence of any CVB 
antigens, making it unlikely that a chronic viral infec- 
tion had occurred to explain the inflammatory process. 
Finally, antibody to CVB, which has previously been 
demonstrated to prevent the spread and replication of 
virus, was present in the serum in amounts sufficient 
to neutralize virus throughout the period of progres- 
sive clinical and histologic muscle disease. 
The fact that the host immune response is 
capable of inducing an inflammatory myositis has been 
known for some time from investigations of EAM (14). 
In addition, Woodruff and Woodruff have obtained 
significant data implicating the immune response in the 
development and perpetuation of muscle tissue injury 
in a similar CVB-induced murine disorder, chronic 
myocarditis (9). In that model, CVB infection results 
in the development of cytotoxic T lymphocytes capa- 
ble of specifically lysing CVB-infected myofibers by 
an H-2 restricted, antibody-independent mechanism 
(9,15). In vivo studies using antithymocyte serum 
confirmed the T cell-dependent nature of this process 
by demonstrating a significant reduction in CVB- 
induced myocarditis with little effect on the ability of 
host defenses to clear virus. 
Further investigations in both murine and pri- 
mate systems have suggested that these specifically 
activated T cells may be reacting to the presence of a 
novel cell surface antigen which is found after CVB 
infection (1  1,12). It is also possible that T cell-depen- 
dent antiviral antibodies react with these antigens via 
complement or nonimmune cell cytotoxic mecha- 
nisms, resulting in myocyte injury. In humans, recent 
studies by Rowe et a1 also have implicated T cells in 
the pathogenesis of I’M by demonstrating large num- 
bers of T cells, probably bearing the HLA-DR anti- 
gen, in the inflammatory infiltrates of muscle (16). 
Thus the clinical, laboratory, and immunologic 
characteristics of murine CVBT-induced myositis bear 
a strong resemblance to human PM and provide an 
ideal model to explore the pathogenesis and treatment 
of this disorder. Furthermore, study of CVBT-induced 
murine myositis can be expected to contribute to an 
overall understanding of the role of virus in the initia- 
tion and maintenance of PM as well as  other collagen 
vascular disorders, and to the mechanisms by which 
the elicited immune responses give rise to the ob- 
served inflammatory reactions. 
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